IBRX — ImmunityBio, Inc. stock price, charts and financials

QT63ImmunityBio, Inc.

ImmunityBio, Inc. (NASDAQ: IBRX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
6.95
-0.20-2.80%
OverviewShort InterestFilings
IBRXQT63ImmunityBio, Inc.·NASDAQ
6.95-2.80%
Filing
Down 2.8% — Filed an 8-K material-event report (2026-08-04) — details in the filing.
Medium confidence
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
RYTM+2.92%$105.78COGT+10.24%$42.84TGTX+5.57%$48.74PCVX+2.17%$54.69IMVT+2.21%$39.36APGE+0.06%$134.19ERAS+3.03%$18.38MIRM-0.25%$104.33
Snapshot
Index-P/E-EPS (ttm)-0.85Insider Own26.00%Shs Outstand1.05BPerf Week-0.29%
Market Cap7.28BForward P/E-EPS next Y-0.15Insider Trans-0.26%Shs Float113.84MPerf Month-22.00%
Enterprise Value8.02BPEG-EPS next Q-Inst Own-Short Float12.83%Perf Quarter-6.46%
Income-855.00MP/S51.99EPS this Y1.76%Inst Trans-Short Ratio10.02Perf Half Y13.38%
Sales140.00MP/B-EPS next Y82.04%ROA-132.15%Short Interest134.40MPerf YTD251.01%
Book/sh-0.83P/C19.10EPS next 5Y-ROE138.69%52W High12.43 -44.09%Perf Year193.25%
Cash/sh0.36P/FCF-EPS past 3/5Y-ROIC-44.51%52W Low1.95 256.41%Perf 3Y203.49%
Dividend Est.-EV/EBITDA-Sales past 3/5Y- 157.40%Gross Margin93.79%Volatility6.35% 6.01%Perf 5Y-35.47%
Dividend TTM-EV/Sales57.25EPS Y/Y TTM-37.10%Oper. Margin-185.41%ATR (14)0.50Perf 10Y9.45%
Dividend Ex-Date-Quick Ratio6.66Sales Y/Y TTM833.33%Profit Margin-606.15%RSI (14)40.99Recom2.00
Dividend Gr. 3/5Y-Current Ratio6.67EPS Q/Q-313.33%SMA20-8.26%Beta0.14Target Price13.00
Payout0.00%Debt/Eq0.12Sales Q/Q158.82%SMA50-9.08%Rel Volume1.48Prev Close7.15
Employees691LT Debt/Eq-1.74EarningsNov 03SMA20016.59%Avg Volume12.79MPrice6.95
IPO DateJul 28, 2015Option/ShortYes / YesEPS/Sales Surpr.-779.93% 2.64%Net Debt/EBITDA-1.27Volume18,934,157Change-2.80%
Analyst Ratings
DateActionAnalystRatingTarget
May-08-26ReiteratedBTIGBuy$13 → $12
Mar-04-26ReiteratedPiper SandlerOverweight$7.00 → $12
Feb-23-26ReiteratedHC Wainwright & Co.Buy$15
Jan-20-26ReiteratedPiper SandlerOverweight$7.00
May-20-25UpgradePiper SandlerNeutral → Overweight
Jan-10-25InitiatedBTIGBuy$6.00
May-12-23DowngradePiper SandlerOverweight → Neutral
Aug-03-22ReiteratedJefferiesBuy$8.00
Latest News
Aug-04-26
Aug-04-2609:51AM
ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimateszacks.com
08:00AM
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Milliongurufocus.com
Jul-30-26
Jul-30-2601:20PM
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drugbenzinga.com
Jul-29-26
Jul-29-2606:45PM
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancerbusinesswire.com
Jul-20-26
Jul-20-2608:30AM
ImmunityBio: Revisiting My Bearish Call After A Strong Rally (Rating Upgrade)seekingalpha.com
Jul-17-26
Jul-17-2612:09PM
ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buyseekingalpha.com
Jul-13-26
Jul-13-2602:29PM
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right NowBenzinga
Jul-10-26
Jul-10-2612:04PM
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout247wallst.com
Jul-07-26
Jul-07-2604:07AM
ImmunityBio: A Long-Term Bull Case Worth Watchingseekingalpha.com
Jun-29-26
Jun-29-2609:01AM
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?zacks.com
Jun-17-26
Jun-17-2607:50AM
Jim Cramer Calls CAVA 'Tasty, Clean, Fun,' Says Make This Biotech 'Your Speculation'Benzinga
Company

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue14011315101100
Cost of Goods Sold Incl. D&A81000009-3
Gross Profit132113151011-93
Selling, General and Administrative Excl. Other15714716913010313571935
Research and Development2322081902322481961404953
Other Operating Expense61401101001
Operating Income-262-256-344-362-351-330-221-67-98
Interest Expense112113132874715960
Unusual Expense
—————————
Non-Operating Income (Expense)-4811762-135-19-5472
Net Income Before Taxes-854-352-414-584-417-350-226-66-97
Income Taxes000000-20-1
Consolidated Net Income-855-351-414-583-417-347-222-66-96
Net Income From Continuing Operations-855-351-414-584-417-350-224-66-96
Net Income-855-351-414-583-417-347-222-66-96
EPS (Recurring)-0.85-0.38-0.59-1.15-1.04-0.89-0.59-0.42-0.30
EPS (Basic, Before Extraordinaries)-0.85-0.38-0.59-1.15-1.04-0.89-0.59-0.42-0.30
EPS (Diluted)-0.85-0.38-0.62-1.15-1.04-0.89-0.59-0.42-0.30
EBITDA-727-224-264-479-352-321-204-57-87
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio50.9816.12118.952,555.18—2,365.125,105.39——
Gross Margin94.29100.00100.00100.00—100.00100.00——
Operating Margin-187.14-226.55-2,293.33-36,200.00—-33,000.00-22,100.00——
Net Margin-610.71-310.62-2,760.00-58,300.00—-34,700.00-22,200.00——
Shares Outstanding1,027920697509400389383383325
Market Capitalization7,1381,8221,7842,5552,0282,3655,1051,452377
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$12.99$9.88$6.76$3.65$0.54● Close Price0.00M0.73M1.47M2.20M2.93MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Cohen CherylDirectorJul 02 '26Sale9.50131,2101,246,941125,386Jul 06
Cohen CherylDirectorJul 02 '26Option Exercise2.9855,979166,817256,596Jul 06
Selecky ChristobelDirectorJul 01 '26Sale9.02159,4781,439,0660Jul 06
Selecky ChristobelDirectorJul 01 '26Option Exercise2.99159,478476,489159,478Jul 06
Selecky ChristobelDirectorJun 30 '26Option Exercise2.981,0002,9831,000Jul 01
Selecky ChristobelDirectorJun 30 '26Sale9.001,0009,0000Jul 01
Selecky ChristobelDirectorJun 29 '26Sale9.0195,722862,2160Jul 01
Selecky ChristobelDirectorJun 29 '26Option Exercise2.9495,722281,38895,722Jul 01
Simon Barry J.DirectorJun 24 '26Sale7.8825,000196,9082,802,788Jun 26
Simon Barry J.DirectorJun 04 '26Sale7.1823,033165,3062,827,788Jun 05
Simon Barry J.DirectorFeb 24 '26Sale12.0175,000900,7882,850,821Feb 26
Selecky ChristobelDirectorFeb 23 '26Sale10.0025,000250,0000Feb 24
Selecky ChristobelDirectorFeb 23 '26Option Exercise2.9825,00074,50025,000Feb 24
Simon Barry J.DirectorFeb 23 '26Sale10.25165,0001,691,1022,925,821Feb 24
SOON-SHIONG PATRICKSee remarksFeb 22 '26Option Exercise0.00114,329029,816,081Feb 24
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.